Asthma: phenotyping and the response to biologics最新文献

{"title":"P202 Real life experience with mepolizumab and comparison with omalizumab in children with severe asthma","authors":"J. Ko, A. Jamalzadeh, S. Makhecha, S. Saglani, A. Bush, L. Fleming","doi":"10.1136/thorax-2021-btsabstracts.311","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.311","url":null,"abstract":"the one type-2 biomarker frequency-weighted in and respectively. contrast, the 814 patients with both biomarkers low at baseline had observed vs predicted rate ratios of 0.86 vs 1.00; the corresponding percentages reduction in asthma attacks were 14% and 0%, respectively. The relative risk associated with biomarkers was consistent across populations, but the absolute risk and the treatment benefit conferred by type-2 biomarkers was greater in a population at higher background risk. The prototype ORACLE scale predicts the excess risk conferred by raised biomarkers which is removed by anti-inflammatory therapy in trial populations. for large-scale paediatric mepolizumab studies, especially given evidence of low Type-2 cytokines in children with severe asthma.","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"136 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133112419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P207 Steroid reduction with omalizumab in severe allergic asthma","authors":"L. Elsey, A. Jefferson, S. Fowler, L. Maguire, S. Khurana, C. Pantin","doi":"10.1136/thorax-2021-btsabstracts.316","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.316","url":null,"abstract":"","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"7 2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125026318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P203 Effectiveness of anti-IL4R therapy following Suboptimal Response to anti-IL5/5R therapy in severe eosinophilic asthma","authors":"Twila A. Mason, A. Hearn, G. d'Ancona, M. Fernandes, C. Roxas, L. Green, L. Thomson, J. Dhariwal, A. Nanzer, D. Jackson","doi":"10.1136/thorax-2021-btsabstracts.312","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.312","url":null,"abstract":"P205 Figure 1 Poster sessions A178 Thorax 2021;76(Suppl 2):A1–A205 on N ovem er 0, 2021 by gest. P rocted by coright. httphorax.bm jcom / T hrax: frst pulished as 10.113orax-2021-B T S abscts.312 on 8 N ovem er 221. D ow nladed fom","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"2020 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122383453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P200 Urinary leukotriene E4 as a biomarker in NSAID exacerbated respiratory disease (N-ERD): a systematic review and meta-analysis","authors":"B. Tailor, M. Marquette, Pc Calder, PJ Curtis, AM Wilson","doi":"10.1136/thorax-2021-btsabstracts.309","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.309","url":null,"abstract":"","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"93 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115171952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P204 COVID-19 in the absence of eosinophils: a case series of confirmed infection whilst on treatment with benralizumab","authors":"C. Francis, A. Hearn, S. Ratnakumar, A. Taylor, J. Duckitt, U. Ahmed, J. Dhariwal, A. Nanzer, D. Jackson","doi":"10.1136/thorax-2021-btsabstracts.313","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.313","url":null,"abstract":"BackgroundBlood eosinopaenia was one of the earliest reported findings in hospitalised patients with COVID-19, questioning whether eosinophils could have an anti-viral or deleterious role in the immune response against SARS-CoV2. Benralizumab is an anti-IL5R monoclonal antibody licensed for the treatment of severe eosinophilic asthma (SEA) and causes the near-complete depletion of blood and tissue eosinophils. As such, it offers the opportunity to explore the impact of eosinopaenia at the time of infection on outcome with COVID-19.MethodPatients started on treatment with benralizumab (up until April 2021) for SEA at our regional asthma centre were contacted by telephone throughout May and June 2021 to establish whether they had experienced a confirmed (PCR-positive) SARS-CoV2 infection since commencing benralizumab. Clinical and demographic characteristics were recorded along with the outcome of infection, including the need for hospitalisation or intensive care admission. Patients requiring hospitalisation were compared to those experiencing mild infections.ResultsData on 268 patients treated with benralizumab was collected with 24/268 (9%) confirming SARS-CoV2 infection with a positive PCR test. Of these 18/24 (75%) experienced mild infections that did not require hospitalisation. Of the 6/24 requiring hospitalisation, the median (IQR) length of stay was 6 (1–8) days. No patients required ICU admission or mechanical ventilation. There was no significant difference in baseline characteristics between hospitalised and non-hospitalised patients. However, it is noteworthy that a higher proportion of hospitalised patients were male (50.0% vs 38.9%) and had a higher mean BMI (32.1 vs 29.5).DiscussionIn the context of drug-induced eosinopaenia with benralizumab, 75% of patients with severe asthma experienced mild COVID-19 disease. This is likely to be an underestimate given that other patients may have experienced an asymptomatic infection or not pursued PCR testing in the context of mild infection. Although caution is needed due to the small sample size, these results do not support a significant role for eosinophils in SARS-CoV2 infection.","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"645 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134101866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P201 To what extent does the prototype ORACLE scale predict treatment benefits? Predicted versus observed impact of anti-inflammatory treatments","authors":"S. Couillard, W. Do, R. Beasley, A. Laugerud, M. Jabeen, S. Ramakrishnan, J. Melhorn, T. Hinks, I. Pavord","doi":"10.1136/thorax-2021-btsabstracts.310","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.310","url":null,"abstract":"","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129101544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P205 Elective inpatient systematic evaluation of difficult to treat asthma; case series demonstrating the clinical value and improved patients outcomes","authors":"A. Cass, A. Mansur","doi":"10.1136/thorax-2021-btsabstracts.314","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.314","url":null,"abstract":"for large-scale paediatric mepolizumab studies, especially given evidence of low Type-2 cytokines in children with severe asthma.","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"87 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126503488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P206 Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis","authors":"M. Oliver, S. Poole, C. Borg, C. Connolly, I. Pavord, T. Hinks, S. Couillard","doi":"10.1136/thorax-2021-btsabstracts.315","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.315","url":null,"abstract":"","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"282 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116507455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P208 Does obesity affect fractional exhaled nitric oxide interpretation in difficult asthma?","authors":"V. Sharma, H. Ricketts, A. Goodfellow, F. Steffensen, D. Cowan","doi":"10.1136/thorax-2021-btsabstracts.317","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.317","url":null,"abstract":"","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130623011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P209 Treatable traits in diagnosis-naïve and untreated patients with suspected asthma – data from the RADICA study","authors":"R. Wang, I. Choudhury, L. Healy, S. Drake, L. Willmore, J. Mitchelle, R. Tudge, A. Simpson, C. Murray, S. Fowler","doi":"10.1136/thorax-2021-btsabstracts.318","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.318","url":null,"abstract":"","PeriodicalId":153163,"journal":{"name":"Asthma: phenotyping and the response to biologics","volume":"9 10-11","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114037186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}